search
Back to results

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (ARRECTOR)

Primary Purpose

Scalp Psoriasis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ARQ-154 Foam 0.3%
ARQ-154 Vehicle
Sponsored by
Arcutis Biotherapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scalp Psoriasis

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • For adult subjects: Participants legally competent to read, write, and sign and give informed consent. For adolescent subjects: Informed consent of a parent(s) or legal guardian, and assent by the subjects, as required by local laws.
  • Males and females ages 12 years and older (inclusive) at the time of consent or assent.
  • Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA) severity of at least Moderate ('3') at Baseline.
  • Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline.
  • A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline.
  • An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline.
  • A PASI score of at least 2 (excluding palms and soles) at Baseline.
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.
  • Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%.
  • Female subject of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception or a barrier method of contraception throughout the study according to Contraception Requirements for the protocol.
  • Females of non-childbearing potential must either be premenarchal, post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status will be confirmed with FSH testing) or have undergone surgical sterilization according to Contraception Requirements for the protocol. Prepubescent females must agree to be abstinent during the study.
  • Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.

Exclusion Criteria:

  • Subjects who cannot discontinue treatment with therapies for the treatment of psoriasis vulgaris prior to the Baseline visit and during the study.
  • Planned excessive exposure to treated area(s) to either natural or artificial sunlight, tanning bed, or other LED.
  • Previous treatment with ARQ-151 or ARQ-154.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.
  • Any condition that in the Investigator's assessment would preclude the subject from participating in the study.

Sites / Locations

  • Arcutis Biotherapeutics Clinical Site 01
  • Arcutis Biotherapeutics Clinical Site 50
  • Arcutis Biotherapeutics Clinical Site 45
  • Arcutis Biotherapeutics Clinical Site 64
  • Arcutis Biotherapeutics Clinical Site 72
  • Arcutis Biotherapeutics Clinical Site 21
  • Arcutis Biotherapeutics Clinical Site 33
  • Arcutis Biotherapeutics Clinical Site 42
  • Arcutis Biotherapeutics Clinical Site 57
  • Arcutis Biotherapeutics Clinical Site 31
  • Arcutis Biotherapeutics Clinical Site 05
  • Arcutis Biotherapeutics Clinical Site 65
  • Arcutis Biotherapeutics Clinical Site 12
  • Arcutis Biotherapeutics Clinical Site 22
  • Arcutis Biotherapeutics Clinical Site 10
  • Arcutis Biotherapeutics Clinical Site 15
  • Arcutis Biotherapeutics Clinical Site 04
  • Arcutis Biotherapeutics Clinical Site 02
  • Arcutis Biotherapeutics Clinical Site 28
  • Arcutis Biotherapeutics Clinical Site 20
  • Arcutis Biotherapeutics Clinical Site 14
  • Arcutis Biotherapeutics Clinical Site 44
  • Arcutis Biotherapeutics Clinical Site 34
  • Arcutis Biotherapeutics Clinical Site 63
  • Arcutis Biotherapeutics Clinical Site 51
  • Arcutis Biotherapeutics Clinical Site 23
  • Arcutis Biotherapeutics Clinical Site 25
  • Arcutis Biotherapeutics Clinical Site 27
  • Arcutis Biotherapeutics Clinical Site 06
  • Arcutis Biotherapeutics Clinical Site 13
  • Arcutis Biotherapeutics Clinical Site 11
  • Arcutis Biotherapeutics Clinical Site 41
  • Arcutis Biotherapeutics Clinical Site 54
  • Arcutis Biotherapeutics Clinical Site 24
  • Arcutis Biotherapeutics Clinical Site 07
  • Arcutis Biotherapeutics Clinical Site 17
  • Arcutis Biotherapeutics Clinical Site 35
  • Arcutis Biotherapeutics Clinical Site 37
  • Arcutis Biotherapeutics Clinical Site 47
  • Arcutis Biotherapeutics Clinical Site 43
  • Arcutis Biotherapeutics Clinical Site 38
  • Arcutis Biotherapeutics Clinical Site 16
  • Arcutis Biotherapeutics Clinical Site 29
  • Arcutis Biotherapeutics Clinical Site 30
  • Arcutis Biotherapeutics Clinical Site 32
  • Arcutis Biotherapeutics Clinical Site 71
  • Arcutis Biotherapeutics Clinical Site 36
  • Arcutis Biotherapeutics Clinical Site 49
  • Arcutis Biotherapeutics Clinical Site 09

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

ARQ-154 Foam 0.3%

ARQ-154 Vehicle

Arm Description

ARQ-154 Foam 0.3%

ARQ-154 Vehicle

Outcomes

Primary Outcome Measures

Scalp Investigator Global Assessment (S-IGA) Score Change
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Body Investigator Global Assessment (B-IGA) Score Change
B-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).

Secondary Outcome Measures

In subjects with a Baseline SI-NRS (Scalp Itch-Numeric Rating Score) pruritus score of ≥ 4, SI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline.
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
SI-NRS (Scalp Itch-Numeric Rating Score) Success, defined as achievement of a ≥ 4-point improvement from Baseline.
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
SI-NRS (Scalp Itch-Numeric Rating Score) Success, defined as achievement of a ≥ 4-point improvement from Baseline.
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
In subjects with a Baseline WI-NRS (Worst Itch-Numeric Rating Score) pruritus score of ≥ 4, achievement of a ≥ 4-point improvement from Baseline
WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch".
PASI-75 (Psoriasis Area and Severity Index-75)
A PASI score is a tool used to measure the severity and extent of psoriasis. Psoriasis Area and Severity Index-75; subjects who achieve a 75% reduction in PASI from Baseline.
Change From Baseline (CFB) in PSD (Psoriasis Symptoms Diary) items related to Itching, Pain, and Scaling (Questions 1, 9, and 11) aggregate score at Week 8
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Psoriasis Symptoms Diary (PSD) related to Scaling (Question 11) = 0 at Week 8
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Psoriasis Symptoms Diary (PSD) Item related to Itching (Question 1) = 0 at Week 8
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Psoriasis Symptoms Diary (PSD) Item related to Pain (Question 9) = 0 at Week 8
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Psoriasis Scalp Severity Index (PSSI-75)
The PSSI is used for the measurement of severity of psoriasis. PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).The PSSI is used for the measurement of severity of psoriasis. PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).
S-IGA (Scalp Investigator Global Assessment) score of 'Clear'
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 4. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
S-IGA (Scalp Investigator Global Assessment) Success
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Change from Baseline (CFB) in PASI (Psoriasis Scalp Severity Index)
A PASI score is a tool used to measure the severity and extent of psoriasis.
S-IGA (Scalp Investigator Global Assessment) Success
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Psoriasis Symptoms Diary (PSD) total Score = 0
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.

Full Information

First Posted
August 25, 2021
Last Updated
April 21, 2023
Sponsor
Arcutis Biotherapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05028582
Brief Title
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Acronym
ARRECTOR
Official Title
A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
August 24, 2021 (Actual)
Primary Completion Date
June 3, 2022 (Actual)
Study Completion Date
June 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Arcutis Biotherapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily for 8 weeks by subjects with scalp and body psoriasis.
Detailed Description
This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle foam is applied once daily for 8 weeks to subjects with scalp and body psoriasis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scalp Psoriasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
432 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ARQ-154 Foam 0.3%
Arm Type
Active Comparator
Arm Description
ARQ-154 Foam 0.3%
Arm Title
ARQ-154 Vehicle
Arm Type
Placebo Comparator
Arm Description
ARQ-154 Vehicle
Intervention Type
Drug
Intervention Name(s)
ARQ-154 Foam 0.3%
Intervention Description
ARQ-154 Foam 0.3%
Intervention Type
Drug
Intervention Name(s)
ARQ-154 Vehicle
Intervention Description
Vehicle
Primary Outcome Measure Information:
Title
Scalp Investigator Global Assessment (S-IGA) Score Change
Description
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Time Frame
8 weeks
Title
Body Investigator Global Assessment (B-IGA) Score Change
Description
B-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
In subjects with a Baseline SI-NRS (Scalp Itch-Numeric Rating Score) pruritus score of ≥ 4, SI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline.
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
Week 8
Title
SI-NRS (Scalp Itch-Numeric Rating Score) Success, defined as achievement of a ≥ 4-point improvement from Baseline.
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
Week 4
Title
SI-NRS (Scalp Itch-Numeric Rating Score) Success, defined as achievement of a ≥ 4-point improvement from Baseline.
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
Week 2
Title
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
Week 1
Title
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
72 Hours
Title
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
Description
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
Time Frame
Day 1
Title
In subjects with a Baseline WI-NRS (Worst Itch-Numeric Rating Score) pruritus score of ≥ 4, achievement of a ≥ 4-point improvement from Baseline
Description
WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch".
Time Frame
Week 8
Title
PASI-75 (Psoriasis Area and Severity Index-75)
Description
A PASI score is a tool used to measure the severity and extent of psoriasis. Psoriasis Area and Severity Index-75; subjects who achieve a 75% reduction in PASI from Baseline.
Time Frame
Week 8
Title
Change From Baseline (CFB) in PSD (Psoriasis Symptoms Diary) items related to Itching, Pain, and Scaling (Questions 1, 9, and 11) aggregate score at Week 8
Description
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Time Frame
Week 8
Title
Psoriasis Symptoms Diary (PSD) related to Scaling (Question 11) = 0 at Week 8
Description
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Time Frame
Week 8
Title
Psoriasis Symptoms Diary (PSD) Item related to Itching (Question 1) = 0 at Week 8
Description
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Time Frame
Week 8
Title
Psoriasis Symptoms Diary (PSD) Item related to Pain (Question 9) = 0 at Week 8
Description
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Time Frame
Week 8
Title
Psoriasis Scalp Severity Index (PSSI-75)
Description
The PSSI is used for the measurement of severity of psoriasis. PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).The PSSI is used for the measurement of severity of psoriasis. PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).
Time Frame
Week 8
Title
S-IGA (Scalp Investigator Global Assessment) score of 'Clear'
Description
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 4. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Time Frame
Week 8
Title
S-IGA (Scalp Investigator Global Assessment) Success
Description
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Time Frame
Week 4
Title
Change from Baseline (CFB) in PASI (Psoriasis Scalp Severity Index)
Description
A PASI score is a tool used to measure the severity and extent of psoriasis.
Time Frame
Week 2
Title
S-IGA (Scalp Investigator Global Assessment) Success
Description
S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).
Time Frame
Week 2
Title
Psoriasis Symptoms Diary (PSD) total Score = 0
Description
The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.
Time Frame
Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For adult subjects: Participants legally competent to read, write, and sign and give informed consent. For adolescent subjects: Informed consent of a parent(s) or legal guardian, and assent by the subjects, as required by local laws. Males and females ages 12 years and older (inclusive) at the time of consent or assent. Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA) severity of at least Moderate ('3') at Baseline. Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline. A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline. An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline. A PASI score of at least 2 (excluding palms and soles) at Baseline. Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks. Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%. Female subject of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception or a barrier method of contraception throughout the study according to Contraception Requirements for the protocol. Females of non-childbearing potential must either be premenarchal, post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status will be confirmed with FSH testing) or have undergone surgical sterilization according to Contraception Requirements for the protocol. Prepubescent females must agree to be abstinent during the study. Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis. Exclusion Criteria: Subjects who cannot discontinue treatment with therapies for the treatment of psoriasis vulgaris prior to the Baseline visit and during the study. Planned excessive exposure to treated area(s) to either natural or artificial sunlight, tanning bed, or other LED. Previous treatment with ARQ-151 or ARQ-154. Females who are pregnant, wishing to become pregnant during the study, or are breast feeding. Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects. Any condition that in the Investigator's assessment would preclude the subject from participating in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Berk, MD
Organizational Affiliation
Arcutis Biotherapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Arcutis Biotherapeutics Clinical Site 01
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85255
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 50
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90212
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 45
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 64
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 72
City
Santa Ana
State/Province
California
ZIP/Postal Code
92701
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 21
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 33
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 42
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 57
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33484
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 31
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 05
City
Orlando
State/Province
Florida
ZIP/Postal Code
32819
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 65
City
Sanford
State/Province
Florida
ZIP/Postal Code
32771
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 12
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 22
City
Plainfield
State/Province
Illinois
ZIP/Postal Code
46168
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 10
City
Rolling Meadows
State/Province
Illinois
ZIP/Postal Code
60008
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 15
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 04
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70605
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 02
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 28
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 20
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 14
City
New Brighton
State/Province
Minnesota
ZIP/Postal Code
55112
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 44
City
Saint Joseph
State/Province
Missouri
ZIP/Postal Code
64506
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 34
City
East Windsor
State/Province
New Jersey
ZIP/Postal Code
08520
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 63
City
Bronx
State/Province
New York
ZIP/Postal Code
10462
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 51
City
Rochester
State/Province
New York
ZIP/Postal Code
14623
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 23
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 25
City
Portland
State/Province
Oregon
ZIP/Postal Code
97223
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 27
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 06
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37922
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 13
City
Arlington
State/Province
Texas
ZIP/Postal Code
76011
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 11
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 41
City
College Station
State/Province
Texas
ZIP/Postal Code
77845
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 54
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 24
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78218
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 07
City
West Jordan
State/Province
Utah
ZIP/Postal Code
84088
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 17
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Arcutis Biotherapeutics Clinical Site 35
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2J 7E1
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 37
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V0C6
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 47
City
Winnepeg
State/Province
Manitoba
ZIP/Postal Code
R3M 3Z4
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 43
City
Fredericton
State/Province
New Brunswick
ZIP/Postal Code
E3B 1G9
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 38
City
Ajax
State/Province
Ontario
ZIP/Postal Code
L1S 7K8
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 16
City
London
State/Province
Ontario
ZIP/Postal Code
N6H 5L5
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 29
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5H 1G9
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 30
City
North Bay
State/Province
Ontario
ZIP/Postal Code
P1B 3Z7
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 32
City
Peterborough
State/Province
Ontario
ZIP/Postal Code
K9J 5K2
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 71
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4W 2N2
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 36
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2J 1C4
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 49
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N8W 1E6
Country
Canada
Facility Name
Arcutis Biotherapeutics Clinical Site 09
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3Z 2S6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

We'll reach out to this number within 24 hrs